SYNERGY(SZ:300636)2022-04-27 16:00Financial Performance - The company's revenue for Q1 2022 was CNY 179,771,415.86, representing a 30.89% increase compared to CNY 137,346,511.89 in the same period last year[3]. - Net profit attributable to shareholders was CNY 26,828,215.64, up 33.22% from CNY 20,137,702.87 year-on-year[3]. - The total operating revenue for the first quarter of 2022 was CNY 179,771,415.86, an increase of 30.9% compared to CNY 137,346,511.89 in the same period last year[22]. - The operating profit for the first quarter was CNY 29,556,664.26, compared to CNY 22,069,808.00 in the previous year, indicating a growth of 34.0%[23]. - The basic earnings per share for the first quarter were CNY 0.1303, compared to CNY 0.0979 in the previous year, representing a growth of 33.3%[24]. Cash Flow - The net cash flow from operating activities surged by 345.97%, reaching CNY 96,438,592.52 compared to CNY 21,624,541.20 in the previous year[9]. - The cash inflow from operating activities for Q1 2022 was CNY 198,574,389.37, compared to CNY 107,593,128.59 in Q1 2021, representing an increase of approximately 84.5%[27]. - The cash outflow from investing activities totaled CNY 148,609,370.00, compared to CNY 119,618,570.55 in Q1 2021, indicating an increase of about 24.2%[28]. - The net cash flow from investing activities was -CNY 128,532,333.42, worsening from -CNY 109,190,557.03 year-over-year[28]. - The cash inflow from financing activities was CNY 37,133,085.40, down from CNY 50,935,500.56 in Q1 2021, a decrease of approximately 27.2%[28]. - The net cash flow from financing activities was -CNY 49,338,103.33, compared to -CNY 57,109,620.00 in the previous year, showing an improvement of about 13.1%[28]. Assets and Liabilities - The company's total assets at the end of the reporting period were CNY 1,965,140,972.54, a 3.06% increase from CNY 1,906,727,705.65 at the end of the previous year[3]. - The total liabilities decreased to CNY 1,003,766,584.28 from CNY 1,018,614,712.28, showing a reduction of 1.5%[20]. - The company's non-current assets totaled CNY 1,332,414,567.32, up from CNY 1,263,170,810.12, reflecting a growth of 5.5%[20]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,484[11]. - The largest shareholder, Mr. Pang Zhengwei, holds 20.98% of shares, totaling 44,006,636 shares, with 33,004,977 shares pledged[11]. - The total number of restricted shares at the end of the period is 33,267,127 shares, primarily due to executive lock-up[14]. Research and Development - Research and development expenses increased by 68.35%, totaling CNY 11,496,727.71, compared to CNY 6,828,900.90 in the same period last year[8]. - Research and development expenses for the quarter were CNY 11,496,727.71, significantly higher than CNY 6,828,900.90 in the same period last year, indicating a 68.5% increase[23]. Inventory and Receivables - The company reported a significant increase in accounts receivable, which rose by 41.47% to CNY 84,379,641.05 from CNY 59,646,125.68 at the beginning of the period[6]. - Accounts receivable increased from 59,646,125.68 CNY to 84,379,641.05 CNY, representing an increase of about 41.5%[18]. - Inventory rose from 373,422,198.77 CNY to 413,003,943.38 CNY, indicating an increase of approximately 10.6%[18]. Financial Expenses - Financial expenses skyrocketed by 2087.68%, amounting to CNY 893,859.53, compared to CNY 40,858.71 in the same period last year[8]. Construction and Expansion - The company successfully raised 360 million CNY through convertible bonds to support the production of various pharmaceutical products[15]. - The second-phase project of the new factory is in the final stages of construction, with two workshops partially in trial production[16]. - The company plans to implement new construction and expansion projects in the second-phase factory, currently in the design phase[16].